How big is MaxCyte, Inc.?

As of Jun 18, MaxCyte, Inc. has a market capitalization of 228.58 million, with net sales of 37.67 million and a net profit of -41.80 million over the latest four quarters. Shareholder's funds are 206.25 million, and total assets are 239.47 million.

As of Jun 18, MaxCyte, Inc. has a market capitalization of 228.58 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 37.67 million, while the sum of Net Profit for the same period is -41.80 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 206.25 million and Total Assets at 239.47 million.

What does MaxCyte, Inc. do?

MaxCyte, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in cell-based medicines. As of March 2025, it reported net sales of $10 million and a net loss of $10 million, with a market cap of $228.58 million.

Overview:<BR>MaxCyte, Inc. focuses on cell-based medicines within the Pharmaceuticals & Biotechnology industry and operates in the micro-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 228.58 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.69 <BR>Return on Equity: -20.50% <BR>Price to Book: 1.15<BR><BR>Contact Details:<BR>Address: 22 Firstfield Rd Ste 110, GAITHERSBURG MD: 20878-1795 <BR>Tel: 1 301 9441700 <BR>Fax: 1 301 9441703 <BR>Website: https://www.maxcyte.com/

Should I buy, sell or hold MaxCyte, Inc.?

Who are in the management team of MaxCyte, Inc.?

As of March 2022, the management team of MaxCyte, Inc. includes Dr. J. Stark Thompson (Non-Executive Independent Chairman), Mr. Douglas Doerfler (President and CEO), and Mr. Ronald Holtz (Senior VP and Chief Accounting Officer), along with several Non-Executive Independent Directors on the Board.

As of March 2022, the management team of MaxCyte, Inc. includes the following individuals:<BR><BR>- Dr. J. Stark Thompson, Non-Executive Independent Chairman of the Board<BR>- Mr. Douglas Doerfler, President, Chief Executive Officer, Executive Director<BR>- Mr. Ronald Holtz, Senior Vice President, Chief Accounting Officer, Executive Director<BR><BR>Additionally, the Board of Directors features several Non-Executive Independent Directors, including Mr. William Brooke, Dr. Richard Douglas, Mr. Stanley Erck, and Mr. John Johnston.

Is MaxCyte, Inc. overvalued or undervalued?

As of March 22, 2022, MaxCyte, Inc. is considered risky and overvalued with a Price to Book Value of 1.15, an EV to EBITDA ratio of -2.00, a negative ROCE of 80.39%, and a year-to-date return of -61.06%, significantly underperforming the S&P 500's 12.22%.

As of 22 March 2022, the valuation grade for MaxCyte, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.15 and a concerning EV to EBITDA ratio of -2.00. Additionally, the Return on Capital Employed (ROCE) stands at a negative 80.39%, further highlighting the company's struggles in generating returns.<BR><BR>In comparison to its peers, MaxCyte, Inc. has a significantly lower EV to EBITDA ratio of -0.5242 compared to Voyager Therapeutics, Inc. at -0.2378 and bluebird bio, Inc. at -0.7970, suggesting that it is less favorably positioned within the industry. Furthermore, the stock has underperformed relative to the S&P 500, with a year-to-date return of -61.06% compared to the index's 12.22%, reinforcing the notion of its overvaluation amidst a challenging market environment.

Is MaxCyte, Inc. technically bullish or bearish?

As of August 6, 2025, MaxCyte, Inc. has shifted to a bearish trend with weak strength, indicated by bearish daily moving averages and negative monthly KST and MACD signals, while underperforming the S&P 500 with a year-to-date return of -61.06%.

As of 6 August 2025, the technical trend for MaxCyte, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by the daily moving averages being bearish and both the KST and MACD on a monthly basis also showing bearish signals. The weekly MACD remains mildly bullish, but this is offset by the overall bearish indicators. Additionally, the stock has significantly underperformed against the S&P 500 over multiple periods, with a year-to-date return of -61.06% compared to the S&P 500's 12.22%.